financetom
Business
financetom
/
Business
/
Creative Media Shares Spike On Heels Of $44 Million PG FR Deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Creative Media Shares Spike On Heels Of $44 Million PG FR Deal
Nov 12, 2025 6:52 AM

Creative Media shares are surging on Wednesday after it inked a deal to sell its lending division to PG FR Holding, LLC, an affiliate of Atlanta-based Peachtree Group.

Based on the lending division's assets and other information as of Sept. 30, the purchase price is estimated at approximately $44 million (net of debt from a 2023 securitization), subject to adjustments.

After accounting for debt repayment, transaction costs, and other factors, CMCT expects net cash proceeds of around $31 million.

The transaction closure is subject to U.S. Small Business Administration approval and other customary closing conditions.

Strategy, CFO Transition

The sale supports CMCT's strategic priorities of expanding its premier multifamily portfolio, strengthening its balance sheet, and enhancing liquidity.

Since outlining these goals in the third quarter of 2024, the company has completed four refinancings across seven assets, extended debt maturities on two multifamily properties, and fully repaid its recourse credit facility.

Post-sale closure, Barry Berlin will resign as Executive Vice President, CFO, Treasurer, and Secretary of the company.

Brandon Hill will succeed him as CFO and treasurer.

Creative Media expects to release third-quarter 2025 earnings results on Nov. 14.

Price Action: CMCT shares are up over 71% at $8.58 at the last check on Wednesday.

Read Next:

WSR Stock Rises On MCB Real Estate Revised Acquisition Proposal

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Boeing Gets Order for Four More 777 Freighters From Turkish Airlines
Boeing Gets Order for Four More 777 Freighters From Turkish Airlines
Jul 2, 2024
09:37 AM EDT, 07/02/2024 (MT Newswires) -- Boeing ( BA ) and Turkish Airlines said Tuesday the airline has ordered four more 777 Freighters to expand its cargo fleet. The companies said that with the order, the airline will operate 12 777 Freighters. The financial details of the order weren't provided. Price: 186.28, Change: -0.42, Percent Change: -0.23 ...
BlackRock Reportedly Outlines New Policies for Climate-Focused Funds
BlackRock Reportedly Outlines New Policies for Climate-Focused Funds
Jul 2, 2024
09:38 AM EDT, 07/02/2024 (MT Newswires) -- BlackRock ( BLK ) will apply new guidelines to $150 billion in investment funds it manages that have climate objectives, according to media reports. Citing a message to clients from Joud Abdel Majeid, the head of investment stewardship, the guidelines will influence how the funds vote on shareholder proposals concerning decarbonization, differentiating them...
US FDA warns website over unlawful sale of weight-loss drugs
US FDA warns website over unlawful sale of weight-loss drugs
Jul 2, 2024
July 2 (Reuters) - The U.S. Food and Drug Administration said on Tuesday it had warned a website called ozempen.com on Tuesday against unlawfully selling versions of Novo Nordisk's weight-loss drugs. The FDA said the website was offering unapproved versions of obesity and diabetes drugs Ozempic and Wegovy. These products are only available pursuant to a prescription from a licensed...
Inozyme Pharma Says US FDA Granted Fast Track Designation to INZ-701 to Treat ABCC6 Deficiency
Inozyme Pharma Says US FDA Granted Fast Track Designation to INZ-701 to Treat ABCC6 Deficiency
Jul 2, 2024
09:40 AM EDT, 07/02/2024 (MT Newswires) -- Inozyme Pharma ( INZY ) said Tuesday that the US Food and Drug Administration has awarded Fast Track designation to INZ-701 to treat ABCC6 deficiency, a disease caused by gene mutations. The designation is intended to accelerate the development and review of treatments for severe or life-threatening conditions that show the potential to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved